The combined annual revenue of just two GLP-1 peptides, semaglutide and tirzepatide, is projected to exceed $55 billion. This figure nearly rivals the revenue of the entire AI large language model industry, demonstrating the massive, often underestimated, economic scale of the market for effective metabolic health solutions.

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

Breakthrough drugs aren't always driven by novel biological targets. Major successes like Humira or GLP-1s often succeeded through a superior modality (a humanized antibody) or a contrarian bet on a market (obesity). This shows that business and technical execution can be more critical than being the first to discover a biological mechanism.

Stevanato has been investing hundreds of millions in new plants to meet biologic and GLP-1 demand, suppressing free cash flow. This heavy capex cycle is now ending. As spending normalizes, the company is set to become highly free cash flow positive, combining margin expansion and revenue growth with significant cash generation.

Eli Lilly is leveraging its massive GLP-1 drug revenue for a long-term strategic play. Instead of just acquiring single assets, the company is investing in global innovation hubs, supercomputing with NVIDIA, and incubators to build a sustainable innovation backbone, aiming to avoid typical patent cliff-driven downturns.

The market fears oral GLP-1s will make injectable suppliers like Stevanato obsolete. However, oral versions are currently only half as effective. Injectables will remain essential for severe cases (morbidly obese, type 2 diabetes) and patients who struggle with strict daily adherence, ensuring continued demand.

Despite intense media hype and rapid initial sales, GLP-1 therapies have only reached a fraction of their potential market. With just 6% of eligible obesity patients in the U.S. and 2% internationally currently on treatment, the runway for future growth remains immense.

Stevanato's margin growth isn't reliant on cost-cutting. It's a result of a product mix shift. Their high-margin "high-value solutions" for biologics are growing at 15-18% annually, while their lower-margin business is growing at 2%. This shift mechanically expands overall EBITDA margins.

The obesity market is evolving beyond maximum weight loss. Key differentiators will become dosing convenience, side effect profiles, and preserving lean muscle. This creates space for novel mechanisms, potentially as add-on therapies to lower GLP-1 doses and mitigate side effects.